WASHINGTON, D.C. (February 8, 2011) – Debra Lappin, president of The Council for American Medical Innovation (CAMI), a partnership of leaders in research, medicine, patient advocacy, academia, education, labor and business dedicated to advancing medical innovation, issued the following statement on the announcement today by the Food and Drug Administration (FDA) proposing a priority review program for innovative medical devices.
“Today’s proposal from FDA’s Center for Devices and Radiological Health (CDRH) is yet another example of the growing recognition of the importance of medical innovation to the health of our nation, our citizens and our economy. The FDA’s leadership in identifying ways to smooth roadblocks in the review and development stages, while keeping safety as the top priority, is a key component to spurring the innovation that will change the lives and health of patients in the U.S.
“The Council believes that continued commitment to medical innovation is the best opportunity to not only bring cutting edge medicines and devices to patients who need them, but to reduce health care costs, create jobs and maintain U.S. global competitiveness. Our 2010 report, Gone Tomorrow? A Call to Promote Medical Innovation, Create Jobs, and Find Cures in America, found that proposals such as CHRH’s Innovation Pathway are essential to help bring the best science to the review and approval of biomedical advances.
“We applaud FDA Commissioner Margaret Hamburg and CDRH Director Jeffrey Shuren for their efforts, and we look forward to working with them to further ensure U.S. leadership in medical innovation.”